The American Medical Association (AMA) is joining forces with the Vaccine Integrity Project to launch an independent review of vaccine safety and effectiveness, a move that comes as the Centers for Disease Control and Prevention’s (CDC) role in vaccine recommendations faces increasing scrutiny. This collaborative effort aims to rebuild trust in the science underpinning vaccine policy, particularly for respiratory viruses like influenza, COVID-19, and RSV, and address concerns about the future of evidence-based immunization guidance.
For decades, the CDC’s Advisory Committee on Immunization Practices (ACIP) has been the primary body responsible for shaping vaccine recommendations in the United States. However, recent developments, including the removal of representatives from major medical organizations like the AMA and the American Academy of Pediatrics from ACIP workgroups, have raised questions about the independence and transparency of the process. The CDC informed these organizations via email that their experts were being disinvited, citing concerns about potential “bias” due to representing specific constituencies.
Restoring Confidence in Vaccine Science
The Vaccine Integrity Project, based at the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), will collaborate with the AMA to convene leading medical societies and public health organizations. The goal is to define a comprehensive set of policy questions and evaluate the risks and benefits of vaccine policies for all populations. This review will focus on immunizations for the 2026–27 respiratory virus season, building upon a previous assessment completed for the 2025–26 season. The project seeks to establish a “structured and durable process” for evaluating vaccine science, according to a press release from the AMA.
“Respiratory viruses hospitalize and kill tens of thousands of Americans every year, and vaccine decisions must be guided by facts, not politics or ideology,” said CIDRAP Director Michael Osterholm, PhD, MPH. “Our goal is to build on our efforts to restore peace of mind for clinicians and patients by ensuring that experts are continuously evaluating vaccine safety and effectiveness using transparent, evidence-based methods.”
The CDC’s Evolving Role and Concerns About Fragmentation
The shift away from relying on traditional medical organizations for vaccine recommendations has sparked concern among public health experts. Dr. William Schaffner, a Vanderbilt University vaccine expert with decades of involvement with ACIP, expressed his worries about a potential “confusing fragmentation of vaccine guidance,” where patients receive conflicting information from the government and their doctors. This fragmentation could erode public trust in vaccines and hinder efforts to control infectious diseases.
The AMA’s involvement in this novel review process signals a proactive response to the changing landscape of vaccine policy. The organization has a long history of advocating for evidence-based medicine and public health initiatives. The launch of the Vaccine Integrity Project is intended to fill the void left by the CDC’s altered approach to vaccine recommendations.
What This Means for Patients and Healthcare Providers
The independent review process spearheaded by the AMA and the Vaccine Integrity Project is expected to provide healthcare providers with a reliable source of evidence-based information on vaccine safety and effectiveness. This is particularly important given the increasing complexity of vaccine schedules and the emergence of new variants of respiratory viruses. The project aims to ensure that vaccine decisions are based on scientific data rather than political considerations.
For patients, the initiative could lead to greater confidence in vaccine recommendations and a better understanding of the risks and benefits of immunization. However, the potential for fragmented guidance remains a concern, and clear communication from healthcare providers will be crucial to address any confusion. The AMA and CIDRAP hope to provide a framework for consistent, evidence-driven recommendations that can be trusted by both clinicians and the public.
The situation highlights a broader trend of increasing skepticism towards public health institutions and a growing demand for transparency in scientific decision-making. The AMA’s involvement in this review process is a step towards addressing these concerns and rebuilding trust in the science of vaccination.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The Vaccine Integrity Project is scheduled to release its initial findings for the 2026-27 respiratory virus season in the fall of 2026. Updates on the project’s progress and findings will be available on the AMA website and the CIDRAP website. Share your thoughts on this evolving situation in the comments below.
